A clinical trial (NCT05494112) is currently underway to evaluate the efficacy of Celastrol in treating obesity by restoring leptin sensitivity [48] (Table 1), which may have important implications for neurodegenerative diseases in the future. The gene discussed is LEP; the disease is neurodegenerative disease.